Arena Pharmaceuticals (NASDAQ:ARNA) Director Tina Susan Nova sold 35,000 shares of the stock on the open market in a transaction dated Monday, April 14th. The shares were sold at an average price of $6.22, for a total value of $217,700.00. Following the sale, the director now directly owns 18,728 shares in the company, valued at approximately $116,488. Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) shares after opening at $6.21 moved to $6.37 on last trade day and at the end of the day closed at $6.35. Company price to sales ratio in past twelve months was calculated as 17.10 and price to cash ratio as 6.27. Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) showed a negative weekly performance of -1.24%.
Lieff Cabraser Heimann & Bernstein, LLP reminds investors of the May 5, 2014 deadline to move for appointment as lead plaintiff in the securities class litigation brought on behalf of those who purchased or otherwise acquired the securities of Galena Biopharma, Inc. (NASDAQ:GALE) between May 9, 2013 and March 17, 2014, inclusive (the “Class Period”). Galena Biopharma Inc. (NASDAQ:GALE) shares fell -7.45% in last trading session and ended the day on $1.74. GALE return on equity ratio is recorded as -435.40% and its return on assets is -113.60%. Galena Biopharma Inc. (NASDAQ:GALE) yearly performance is -25.64%.
Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA) on Apr. 2 announced the appointment of Hugh M. Cole to the position of senior vice president and chief business officer. Mr. Cole will be responsible for global business and corporate development, licensing and strategic planning. Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA) shares moved down -4.70% in last trading session and was closed at $6.69, while trading in range of $6.23 – $7.05. Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA) year to date (YTD) performance is -1.91%.
MannKind Corporation (NASDAQ:MNKD) shares continued their decline on Monday following the news that a potential rival has filed for an IPO, says a report from WallStreetPR. MannKind Corporation (NASDAQ:MNKD) weekly performance is -3.98%. On last trading day company shares ended up $6.28. MannKind Corporation (NASDAQ:MNKD) distance from 50-day simple moving average (SMA50) is 7.67%. Analysts mean target price for the company is $7.57.
Leave a Reply